Project Details
Project Description
Randomised Phase II trial to improve the outcomes of children and adolescents diagnosed with ALL with a high risk first relapse by determining if the addition of a new therapeutic agent (Bortezomib) to the standard chemotherapy treatment protocol (ALL-R3) will improve rates of subsequent relapses and provide effective disease control in children with HR-ALL.
Short title | IntReALL HR |
---|---|
Acronym | IntReALL HR |
Status | Finished |
Effective start/end date | 1/10/18 → 31/10/22 |
Funding
- Kids' Cancer Project: A$416,422.00